Condition (MeSH)
Central Nervous System Fungal Infections
ClinicalTrials.gov lists 61 trials for Central Nervous System Fungal Infections or a narrower condition beneath it. Pfizer has the most among industry and government lead sponsors, with 12.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
2 of the 61 trials are tagged with Central Nervous System Fungal Infections itself; the rest are tagged with a narrower condition beneath it.
When did Central Nervous System Fungal Infections trials start? (21)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 6
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 4 |
| 2025 | 1 |
| 2024 | 1 |
| 2023 | 3 |
| 2022 | 1 |
| 2021 | 2 |
| 2020 | 3 |
| 2019 | 2 |
| 2017 | 1 |
| 2016 | 2 |
Showing 10 of 21 earlier years.
No forecast is made for this condition: it averages 2.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 5 trials still running at the 2026-10-09 snapshot; registered median of 26 months across 21 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Central Nervous System Fungal Infections trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 4 |
| Phase 1/2 | 2 |
| Phase 2 | 8 |
| Phase 2/3 | 3 |
| Phase 3 | 7 |
| Phase 4 | 6 |
| Not applicable | 21 |
| Observational | 10 |
How many Central Nervous System Fungal Infections trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 8 |
| Enrolling by invitation | 1 |
| Completed | 36 |
| Terminated | 2 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Central Nervous System Fungal Infections trials? (7)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Pfizer | 12 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 8 |
| National Hospital for Tropical Diseases, Hanoi, Vietnam | 3 |
| ANRS, Emerging Infectious Diseases | 2 |
| Matinas BioPharma Nanotechnologies, Inc. | 2 |
Showing 5 of 7 sponsors.
Which drugs are being tested for Central Nervous System Fungal Infections? (6)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| AMPHOTERICIN B | 18 |
| Flucytosine | 11 |
| Itraconazole | 2 |
| Amphotericin B Deoxycholate | 2 |
| Anidulafungin | 2 |
Showing 5 of 6 drugs.
Interventions as named in the registry (9)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Fluconazol | 26 |
| Voriconazole 1% | 2 |
| liposomal Amphotericine B | 2 |
| MAT2203 | 2 |
| Oteseconazole with Flucytosine - antifungal therapy 4 | 1 |
Showing 5 of 9 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Central Nervous System Fungal Infections trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Anemia | 110 | 2 |
| Grade 4 Serious AEs | 80 | 1 |
| Grade 3 Serious AEs | 78 | 1 |
| Hyponatremia | 36 | 2 |
| Meningitis cryptococcal | 35 | 2 |
Showing 5 of 10 adverse events.
Which publications cover Central Nervous System Fungal Infections? (5)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Evidence for fungal infection in cerebrospinal fluid and brain tissue from patients with amyotrophic lateral sclerosis. | International journal of biological sciences | 2015 | Yes |
| Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis. | Antimicrobial agents and chemotherapy | 2006 | Yes |
| Recurrent blastomycosis of the central nervous system: case report and review. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2000 | Yes |
| Multicenter Evaluation of BioFire FilmArray Meningitis/Encephalitis Panel for Detection of Bacteria, Viruses, and Yeast in Cerebrospinal Fluid Specimens. | Journal of clinical microbiology | 2016 | No |
| Aspergillosis case-fatality rate: systematic review of the literature. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2001 | No |
Sub-conditions in MeSH (2)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.